Talazoparib OverviewTalazoparib (trade name Talzenna, BMN-673) is an orally available poly ADP ribose polymerase (PARP) inhibitor currently in development by Pfizer for the treatment of advanced breast cancer patients with germline BRCA mutations. Talazoparib is similar to the first in class PARP inhibitor, olaparib. The U.S. FDA approved Talzenna (talazoparib) for patients with a germline BRCA-mutated, HER2-negative locally advanced or metastatic breast c...
Read more Talazoparib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Talazoparib
Recent Talazoparib Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Capsule: 0.25mg, 1mg
Other drugs which contain Talazoparib or a similar ingredient: (1 result)
- TALZENNA Talazoparib Tosylate